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1. Introduction
Hypertension is the most frequently treated disease in internal medicine. More than 1 billion
people worldwide suffer from hypertension. Hypertension leads to cardiovascular end-organ
damage increasing morbidity and mortality and is related with high costs to society, making
this disease an important public health challenge. Sonography is a crucial diagnostic tool in
the evaluation of a hypertensive patient. It is used both for the search of secondary forms of
hypertension and for the identification of hypertensive end organ damage. There are several
ultrasound examinations that may be warranted in hypertension. Abdominal ultrasound is
recommended by several guidelines for the basic diagnostic workup in every newly diagnosed
hypertensive patient. Doppler sonography of the renal arteries is reasonable only in a subset of
hypertensives that are at increased risk of renal artery stenosis. Echocardiography is able to
reveal cardiac end organ damage in terms of hypertensive heart disease. Ultrasound of the carotid
arteries is frequently used to detect and evaluate in the case of hypertension-induced vascular
end organ damage. The assessment of the intima-media thickness allows the detection of early
stages of atherosclerotic wall changes. Prior to any structural vascular damage that may be
visualized by ultrasound techniques, hypertension leads to functional changes of the endo‐
thelium, called endothelial dysfunction. Endothelial dysfunction encompasses a variety of
changes in vascular function including a reduced endothelium-dependent vasodilation. This
can be diagnosed by sonography measuring the diameter changes of the brachial artery in
response to predefined endothelial stimuli. Flow-mediated dilation in response to hyperemia is
regarded as the gold-standard in the non-invasive assessment of endothelial dysfunction. To
date, it is rather used scientifically than in daily clinical practice. The present chapter provides
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an overview on the practical performance of all of these ultrasound techniques in the approach
to hypertension.
2. Abdominal ultrasound
The use of abdominal ultrasound in the evaluation of hypertension is twofold.
• In the detection of a secondary forms of hypertension.
• In the evaluation of subclinical organ damage induced by hypertension.
In the current European Society of Cardiology/European Society of Hypertension (ESC/ESH )
guidelines for hypertension the use of abdominal ultrasound is recommended as a part of the
evaluation of hypertensive individuals. The abdominal ultrasound supplies information about
the etiology of hypertension as well as possible end organ damages.
The main interest is the morphology of the kidneys, the adrenal glands and of the aorta. Due
to their retroperitoneal position, kidneys are completely and easily detectable. A 3.5-5 MHz
probe is typically used to scan the kidney. The examination from dorsolateral allows the
evasion of the intestinal loops and thus allows for a non-overlapping imaging in the supine
position. The formerly widely spread examination in the lateral recumbent position is
nowadays used only in exceptional cases. Renal ultrasound has now almost completely
replaced intravenous urography in the anatomical exploration of the kidney. While the latter
requires the injection of potentially nephrotoxic contrast medium, ultrasound is non-invasive
and provides the necessary anatomic data about kidney size and shape, cortical thickness,
urinary tract obstruction and renal masses [1]. Renal parenchymal disease is one of the most
common causes of secondary hypertension which leads to a wide spectrum of morphologic
alterations. The finding of bilateral upper abdominal masses at physical examination is
consistent with polycystic kidney disease and should warrant an abdominal ultrasound
examination. Acute parenchymal inflammatory processes like crescentic glomerulonephritis
or acute interstitial nephritis sometimes predisposes individuals to measurable organ swelling.
The cortical and medullary pyramids have in this case an anechoic profile. However, the
morphological alterations seen via ultrasound in the acute kidney processes are less prominent
than those seen in chronic kidney damage. Thus, the diagnostic performance in acute inflam‐
matory renal disease is less effective. Chronic parenchymal diseases, such as chronic interstitial
nephritis, glomerulonephritis or nephrosclerosis contribute to a progressive decrease in organ
size. A kidney size below 90 mm should be interpreted as pathological. Over the course of the
organ decrease, small scarring cortical retractions develop, which give the kidney surface a
humped aspect. The renal parenchyma develops a hyperechoic pattern through progressive
scarring. The border between parenchyma and pyelon becomes progressively nondescript. A
variety of chronic parenchymal diseases can lead to the morphological end stage of a shrunken
kidney. Sonographically, it is not possible to differentiate whether small kidneys are the cause
or the result of hypertension. A unilateral small kidney as a possible indicator for a hemody‐
namic relevant renal artery stenosis should always lead to a further evaluation of the renal
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arteries. Renal cell carcinomas as a rare cause of hypertension are depicted as a well delimitable
structure from the surrounding tissue. Usually they can be depicted via ultrasound when they
exceed 1 cm. With increasingly size there is an increase in their inhomogeneity, so that it is
possible to detect areas of liquefied necrosis for example.
In the screening of secondary forms of hypertension abdominal ultrasound plays also a role
in the depiction of the adrenal glands. For this purpose a detailed knowledge of the local
anatomy is required. The adrenal glands are located within the retroperitoneum. The left
adrenal gland, lacking the acoustic window of the liver and being obscured by air in the
stomach, is inherently more difficult to scan than the right adrenal gland. On the right side,
the right kidney and the inferior vena cava are landmarks for the examination of adrenal
glands, whereas on the left side the aorta, the lower pole of the spleen and the upper pole of
the kidney are points of orientation. The right adrenal gland is usually scanned with a right
transcostal scan or a subcostal flank scan or oblique subcostal scan. On the left side it is better
to use an intercostal flank scan through the spleen. The normal sized adrenal glands are only
visible with trained examination techniques and by using high resolution technology, whereas
enlarged adrenal glands are detectable in a high percentage of cases. Thirty percent of cases
of primary aldosteronism are caused by adrenal adenomas. Seventy percent of cases are caused
by adrenal hyperplasia. There are rare cases of adrenal carcinoma and the autosomal dominant
condition of glucocorticoid remediable aldosteronism [2]. The micronodular hyperplasia is not
possible to be detected via sonography. Adrenal adenomas have a round to oval shape and
are uniformly hypoechoic with smooth margins, although some lesions have scalloped borders
(polycyclic). Adenomas occasionally have an inhomogeneous appearance. Autopsy statistics
indicate that they are quite common (10–20%), but most adenomas (90%) produce no endocrine
symptoms, they are silent and too small to be detected by ultrasound. In one study the average
size of adenomas was reported to be 1.5 cm, although they may exceed 5 cm in diameter. In a
small percentage of patients adenomas are bilateral. Functioning and nonfunctioning adeno‐
mas are indistinguishable by their sonographic features [3]. Thus, ultrasound is not a sufficient
test in the morphologic diagnosis of Conn syndrome. Upon the detection of a high aldosterone-
to-renin ratio and after a confirmation test (e.g. suppression after administration of sodium
chloride) the use of a CT or MRT scan is indicated. On the other hand, the detection of a
unilateral adrenal mass seen in the ultrasound should be followed by a laboratory evaluation
for the evaluation of Conn-Syndrome.
Phaeochromocytoma, a tumor of the adrenal medulla, is a rare secondary cause of hyperten‐
sion (0.2 – 0.4% of all cases of elevated blood pressure) with an estimated annual incidence of
2 – 8 per million population.[4]. It can be inherited or acquired. Hypertension occurs in about
70% of all cases of phaeochromocytoma, being stable or paroxysmal in approximately equal
proportions. The diagnosis is based on establishing an increase in plasma or urinary catechol‐
amines or their metabolites (e.g. (nor-) metanephrines). Following the appearance of clinical
symptoms (hypertension and tachycardia caused by increased catecholamine secretion),
pheochromocytoma can be detected in 80-90% of cases via abdominal ultrasound. Most
pheochromocytomas are already several centimeters in diameter when diagnosed. They have
smooth margins, a round shape, and an inhomogeneous or complex echo structure. Hypoe‐
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choic liquid components may also be observed. A spectrum of appearances is possible.
Pheochromocytomas are bilateral in approximately 10% of cases and extra-adrenal in 10–20%.
The organ of Zuckerkandl should be looked for at the level of the origin of the inferior
mesenteric artery, anterior to the aorta. Other extra-adrenal sites are the renal hilum, bladder
wall, and thorax. Pheochromocytoma is occasionally seen posterior to the renal vein in
transverse scans. Rarely, pheochromocytoma is diagnosed in the setting of multiple endocrine
neoplasia (MEN). About 2% to 5% of pheochromocytomas are malignant. In recent years
endosopic sonography is being used to obtain an adrenal gland biopsy [5-7].
Abdominal ultrasound is also being used in the evaluation of hypertension induced end-organ
damage. Vascular end-organ damage may be visualized as atherosclerotic as well as aneur‐
ysmatic wall alterations, e.g. of the aorta. In the elderly (> 65 years) approximately 60% of the
patients with hypertension have an isolated systolic hypertension. This is a result of the
diminished elasticity of the large arterial vessels. Ultrasound can indicate a morphological
correlate in form of a manifest aortosclerosis. Besides vascular end-organ damage abdominal
ultrasound detects renal end organ damage. The correlate of hypertensive end-organ damage
of the kidney is (benign) nephrosclerosis. The sonographic features include a reduced size,
hyperechoic parenchyma, indefinite margin of parenchyma and pyelon, and scarring cortical
retractions. As stated above, this unspecific sonographic appearance does unfortunately not
allow a differentiation between cause and result of hypertension.
3. Echocardiography
Hypertension is one of the most important risk factors for heart failure with increasing risk in
all age groups. The lifetime risk for developing heart failure is doubled for subjects with blood
pressure > 160/100mm Hg compared to those with blood pressure < 140/90 mm Hg [8]. Systolic
and diastolic heart failure are both associated with hypertension. There are several mecha‐
nisms, alone or in combination, leading to development of heart failure in the presence of
hypertension: left ventricular hypertrophy (LVH), chamber remodeling, hemodynamic load
and coronary microvascular disease with impaired coronary hemodynamics. To assess
subclinical organ damage, such as ventricular hypertrophy, echocardiography is more
sensitive than electrocardiography [9], which is a routine examination in all subjects with high
blood pressure. However, the ESC/ESH guidelines suggest that in patients with low and
intermediate cardiovascular risk an echocardiography should be performed for better global
cardiovascular risk stratification which may implicate the appropriate pharmacological
treatment [10]. The role of echocardiography is not limited to identification of (sub-) clinical
organ damage in the pre-treatment phase. Since changes of the left ventricular hypertrophy in
response to treatment are associated to cardiovascular fatal and non-fatal events [11], echo‐
cardiography can also be used to monitor treatment’s success and re-assess overall risk.
Left ventricular hypertrophy is the first step toward the development of hypertensive heart
disease. The echocardiographic evaluation of LVH includes measurements of the interven‐
tricular septum, left ventricular posterior wall thickness and end-diastolic diameter. Upon
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these parameters obtained by M-Mode at the end of diastole (under two-dimensional control),
the left ventricular mass is calculated according to the proposed formula [12]. Since LV mass
is depended on gender and obesity, the thresholds for presence of LVH mass are indexed to
body surface area and estimated for men (above 125g/m2) and for women (above 110g/m2) [10].
The adaptation of the left ventricle to hypertension is heterogenic and can be classified in three
geometric patterns based on the LV mass and on the index of relative wall thickness (LV wall
thickness / chamber radius). An increased ratio ≥ 0.42 combined with increased mass is referred
to as concentric hypertrophy. The term eccentric hypertrophy refers to subjects with normal
wall to radius ratio (< 0.42) but increased LV mass. The last pattern, the concentric remodeling,
refers to subjects with normal ventricular mass but increased ratio (≥ 0.42). All three types of
chamber remodeling in response to hypertension are related to increased cardiovascular risk.
Interestingly, the incidence of cardiovascular events correlates with changes in geometric
adaptation, independent of changes of the LV mass. The development or the persistence of a
concentric geometry during treatment has been found to be associated with a greater incidence
of cardiovascular events [13]. In the Losartan Intervention For Endpoint reduction in hyper‐
tension (LIFE) study [11] a regression of the left ventricular mass of about 25g/m2 was associ‐
ated with a 20% reduction in the incidence of the primary endpoint (cardiovascular mortality,
myocardial infarction, stroke). Recent data have furthermore reinforced the predictive value
of echocardiography in hypertensive patients. 35.000 normotensive and hypertensive partic‐
ipants with normal left ventricular ejection fraction were studied retrospectively. An abnormal
left ventricular geometric pattern was found in 46% of the patients (35% with left ventricular
concentric remodeling and 11% with LVH) and was associated with a double-risk of all-cause
mortality compared to the patients with normal left ventricular geometry [14]. A prospective
trial showed that hypertensive patients with echocardiographic LVH had significantly higher
all-cause mortality and cardiovascular events [15]. Beyond the lower incidence of cardiovas‐
cular events, including sudden death, in patients with regression of echocardiographic left
ventricular hypertrophy or a delayed increase in left ventricular mass [11], treatment-induced
changes of left atrium dimension and ventricular geometry are also correlated with cardio‐
vascular event rates [16, 17].
Even before evidence of left ventricular hypertrophy is present and before hypertension in
young normotensive male offspring of hypertensive parents has developed, diastolic dys‐
function may develop as an early end organ damage due to hypertension [18]. Patients with
diastolic heart failure (also referred as heart failure with preserved ejection fraction) show
similar long term impairments as patients with systolic heart failure [19]. The importance of
an early recognition of diastolic dysfunction is imperative. Arterial hypertension with or
without hypertrophy is the main cause of diastolic dysfunction, namely the inability of the
heart to adequately fill with blood during diastole. There are several factors which lead to
diastolic dysfunction in hypertension by impeding the active or passive phases of diastole. Of
these, contractile alterations in myocytes, structural ventricular hypertrophy, extracellular and
perivascular fibrosis, and myocardial ischemia are most often implicated. The European
Society of Cardiology has recognized diastolic dysfunction diagnosed by echocardiography
as criterion for the diagnosis of diastolic heart failure [20]. There are a number of specific
echocardiographic indicators of diastolic dysfunction obtained during the examination. The
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major four parameters include transmitral Doppler inflow velocity patterns, pulmonary
venous Doppler flow patterns, tissue Doppler velocities and color M-mode flow propagation
velocity (Vp). Transmitral Doppler flow is acquired by placing a pulsed wave (PW) sample
volume at the level of the tips of the mitral leaflets in the apical four-chamber view. Normally,
the ventricular inflow consists of an early (E) and a late filling peak (A). Respectively, the early
filling peak velocity (E) and the late (atrial) peak velocity (A) should be recorded. In normal
young individuals, more forward flow occurs during the early diastole largely due to the rapid
decline in left ventricular pressure during the isovolumetric relaxation time (IVRT). Conse‐
quently, the E/A ratio is > 1 correlating with a normal relaxation. An E/A ratio < 1 together with
prolonged IVRT and deceleration time (DT, rapid decline of the E) indicate an abnormal
relaxation. By considering these three parameters two more patterns of impaired diastolic
function are known: the “pseudonormal” pattern which turns to an impaired relaxation
pattern when a Valsalva maneuver is performed and the restrictive pattern. The last one,
occurring mostly in patients with restrictive cardiomyopathies (e.g., infiltrative sarcoidosis,
endomyocardial fibrosis) and dilated cardiomyopathies with poor systolic function which is
associated with increased mortality [21]. Unfortunately, mitral flow is influenced not only by
the diastolic properties of the LV but also by other factors, including preload, afterload, heart
rate and the presence of arrhythmias. Another indicator, the pulmonary venous flow can be
used to assess diastolic function but it is also limited in case of mitral valve disease, heart block
and tachycardia. A more precise assessment of the diastolic function can be made by using the
tissue Doppler imaging (TDI). This enables the measurement of frequency Doppler shifts
caused by myocardial motion as the mitral annulus recoils back toward the base in early (e')
and late (a') diastole. The peak waves (e´ and a´) are obtained in analogy to those recorded by
the mitral flow. TDI enables, depending of the placement of the sample volume, assessment
of global or regional diastolic function. In patients with hypertension and hypertrophy,
diastolic dysfunction is more evident at the basal septal segments [22]. The E/e' ratio (with e'
assessed at a lateral segment) has been identified as the best parameter for diagnosis of diastolic
heart failure [23]. An E/e' ratio below 8 is associated with normal filling pressures and a ratio
> 12 to 15 is associated with elevated filling pressures. For values between 8 and 12 additional
echocardiographic parameters (e.g., use of Valsalva with transmitral Doppler, pulmonary
venous flow) are recommended to correctly classify diastolic function. By using the Doppler
color M-mode another index of diastolic dysfunction, the propagation velocity of early
diastolic flow (Vp) into the ventricle has been proposed. This index seems to be independent
of the load conditions and can be useful to unmask diastolic dysfunction in hypertensive
patients with pseudonormal mitral flow. However, in patients with normal left ventricular
function the Vp may be normal despite an impaired left ventricular relaxation indicating a
major limitation of the index. Beside diastolic dysfunction, an enlarged left atrium was found
in patients with hypertension and preserved ejection fraction and is associated with elevated
filling pressures of the left ventricle leading to clinical heart failure [24].
As described earlier, echocardiography assesses two main features of the hypertensive heart
disease, left ventricular hypertrophy and diastolic dysfunction. Systolic dysfunction occurring
in the presence or not of the aforementioned changes is assessed in the clinical practice by
echocardiography. Assessment of the ejection fraction can be made visually, it requires
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however a high level of expertise and is limited by subjectivity. Quantified, objective meas‐
urements of the LV systolic function have become standard practice in echocardiography. One
parameters of the systolic function is fractional shortening obtained from M-Mode tracings in
the parasternal long axis (method according to Teichmann). Though it is a simple and quick
method, it is limited by the fact that it provides information about contractility along a single
line. If regional wall motion abnormalities occur (e.g. in the presence of coronary artery disease)
the severity of the dysfunction may be under - or overestimated, depending if the region of an
abnormal wall motion is interrogated or not. As long as this method is only valid in symmet‐
rically contracting hearts, it is inappropriate for the remodeled ventricles of patients with heart
failure. The European and American guidelines recommended the biplane method of discs
(modified Simpson’s rule) as the echocardiographic method of choice for volume measure‐
ments and estimation of ejection fraction [25, 26]. The principle underlying this method is that
the total LV volume is calculated from the summation of a stack of elliptical discs. The height
of each disc is calculated as a fraction of the LV long axis based on the longer of the two lengths
from the two and four-chamber views. The cross-sectional area of the disk is based on the two
diameters obtained from the two- and four-chamber views. The method can also be used with
one single plane, when two orthogonal views are not available. In this case, the presence of
any extensive wall motion abnormalities may limit the results [25]. Practically, the endocardial
borders in the apical 4- and 2-chamber views in end-diastole and end-systole are traced
manually or automatically. The end-diastolic and end-systolic volumes (EDV, ESV) are
calculated and the ejection fraction is estimated as follows: Ejection fraction = (EDV – ESV) /
EDV. The reference values for the ejection fraction do not differ between men und women. An
EF > 55% indicates a normal systolic function. An EF between 45-54% suggests a mildly
abnormal function and an EF between 30-44% a moderately abnormal systolic function. A
severely abnormal left ventricular function is indicated by an EF < 30%. This 2-D approach to
assess EF is based on geometric assumptions, which are invalid in a nonsymmetrical contract‐
ing, remodeled ventricle. Over the last decade, several three-dimensional (3-D) echocardio‐
graphic techniques became available to measure LV volumes and mass. 3-D echocardiography
does not rely on geometric assumptions for volume/mass calculations and is not subject to
plane positioning errors, which can lead to chamber foreshortening. Compared to the gold-
standard for assessment of left ventricular volumes and EF, the cardiac magnetic resonance,
3-D echocardiography showed significantly better agreement (smaller bias), lower scatter and
lower intra- and inter-observer variability than 2-D echocardiography [27, 28]. Furthermore,
3-D echocardiography is also used in the assessment of diastolic function, as it is independent
of load conditions.
In summary, echocardiography is a necessary diagnostic tool for risk stratification of pa‐
tients with hypertension before treatment but also for follow-up assessment of end-organ
damages during treatment. In 25-30% of hypertensive patients with low or moderate car‐
diovascular risk (based on risk factor evaluation and ECG),  an increase of  the LV mass
may be identified by echocardiography leading to higher risk stratification and changes of
therapeutic strategy [29, 30].
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4. Doppler ultrasound of renal arteries
Renovascular hypertension is the second most common cause of secondary hypertension in
approximately 2% of adult patients who present with blood pressure elevation when assessed
in specialized centres [31]. This is caused by one or more stenoses of the extrarenal arteries,
which in the elderly population have frequently an atherosclerotic nature. Fibromuscular
dysplasia accounts for up to 25% of total cases and is the most common variety in young adults.
Unfortunately there is not any optimal screening test available for the time. A screening test
should have a high sensitivity in order to keep the false negative results in the lowest possible
level. The Doppler ultrasound of renal arteries allows an analysis of the renal perfusion.
According to various studies the sensitivity and specificity of Doppler ultrasound in the
diagnosis of renal artery stenosis lies approximately at 90% [32, 33]. Due to the fact that
renovascular hypertension in individuals with mild and medium hypertension has a preva‐
lence below 1%, an unselective examination of all individuals with hypertension would lead
to a high rate of false positive results. That would result to a high rate of unnecessary angiog‐
raphies. On the other hand in a preselected population of hypertensives with clinical impli‐
cations of increased probability of renal artery stenosis the Doppler ultrasound of the renal
arteries is a very appropriate screening examination, due to the fact that the prevalence of
renovascular hypertension in acute, severe and resistant hypertension is significantly higher
(10-45%). In other words, the use of Doppler ultrasound as a diagnostic tool in a selected
population, has a significantly higher positive predictive value with a still acceptable negative
predictive value.
Clinical signs for a renovascular hypertension include the following:
• Hypertension in individuals younger than 30 years of age
• A unilateral small kidney or a difference in renal size more than 1.5cm
• Generalized atherosclerosis
• Abdominal bruit with lateralization,
• Resistant hypertension, defined as hypertension refractory to treatment with at least three
antihypertensive drugs (including a diuretic agent)
• An elevation of the serum creatinine level > 30% under the treatment with an ACE inhibitor
or an AT1-receptor antagonist
It should be mentioned, that a difference of more than 1.5 cm in length between the two
kidneys, which is usually considered as being diagnostic for renal artery stenosis is only found
in 60 – 70% of the patients with renovascular hypertension [34].
The examination itself can be limited by factors such as bowel gas, obesity, cooperation of the
patient and from the fact that it is a highly operator dependent examination. The atherosclerotic
induced renal artery stenosis is easily detectable, because it usually involves the ostium and
the proximal 1/3 of the renal artery. On the other hand fibromuscular dysplasia involves the
distal 2/3 of renal artery and their segmental branches and is thus difficult to depict. With
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today’s ultrasound technology it is possible to visualize approximately 88% of all main and
accessory renal arteries [35]. In every renal artery angle corrected flow velocity measurements
should be performed in at least 5 points. A velocity of 60-100cm/s is considered as normal,
whereas a 70% stenosis leads to velocities of at least 180-200cm/s. Stenoses proximal to the
ostium are easily obtainable with an epigastric transverse scan and distal stenoses or stenoses
of segmental branches are better seen with a longitudinal flank scan (lateral position).
Additional intrarenal scanning permits the diagnosis of renal artery stenosis without direct
imaging of the main renal artery. In 1994, Schwerk et al. introduced the Resistive Index (RI)
obtained in the interlobar arteries as a reliable indirect parameter for detecting renal artery
stenosis. The RI is a ratio of peak systolic and end diastolic velocity, derived from the Doppler
spectrum of any vessel. The authors calculated the side-to-side difference of intrarenal RI > 5%
with the lower RI in the post-stenotic kidney. Sensitivity and specificity were 100% and 94%,
respectively, for moderate and severe RAS [36]. In the meantime, intrarenal RI has been
frequently evaluated for different nephrological issues [37, 38]. In a single prospective study
a high intrarenal RI was found to be negatively correlated with the outcome of intervention in
patients with atherosclerotic renal artery stenosis [39]. A high RI (RI ≥ 80) was felt to reflect
advanced renal damage, which would explain the interventional treatment failure. Rader‐
macher et al. [39] investigated the efficacy of angioplasty of a renal artery stenosis in depend‐
ence of the RI. They concluded that an increased renal resistance index > 0.8 is associated with
a poor prognosis despite correction of the stenosis. To date, the clinical impacts of these
findings are discussed controversially.
5. Ultrasound of carotid arteries
The carotid wall thickening is an early marker of atherosclerosis and subclinical organ damage.
It precedes the evolution of arteriosclerotic plaques. Ultrasound of the carotid arteries
constitutes a very good opportunity to evaluate hypertension-induced vascular end organ
damage. Several cardiovascular risk factors including male sex, ageing, elevated blood
pressure, diabetes, smoking and obesity are positively associated with increased carotid
intima-media thickness (IMT) in observational and epidemiological studies. Above these
factors, high systolic blood pressures have the greatest effect on IMT [40]. An IMT > 0.9 mm
in the common carotid artery is generally seen as abnormal; however there is a continuous
relationship between IMT and cardiovascular events. An intima-media thickness (IMT) > 0.9
mm or the presence of a carotid plaque predict the occurrence of stroke and myocardial
infarction [2, 41]. Particularly, in a meta-analysis of data from 8 studies in general populations,
including about 37,000 subjects who were followed up for a mean of 5.5 years, the risk for a
myocardial infarction increases by 10-15% and the stroke risk by 13-18% for every 0.1 mm
increase of the IMT [42]. For the assessment of CVD risk, the carotid artery wall, rather than
the degree of luminal narrowing, is examined to identify areas of increased thickness and non-
occlusive atherosclerotic plaque, which represent early stages of arterial injury and athero‐
sclerosis. Furthermore, the detection of early signs of vascular damage has to include
ultrasound not only of the common carotid arteries, but of bifurcations and/or internal carotids
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where atherosclerosis progresses more rapidly and plaques are more frequent [43]. Ultrasound
imaging of the far wall of the carotid artery produces two echogenic lines, which correspond
to the lumen-intima interface and the media-adventitia interface. The current ultrasound
technology enables in the clinical practice the combined measurement of the thickness of the
intimal and medial layers of the arterial wall which constitute the IMT. Carotid plaque is
defined as the presence of focal wall thickening that is at least 50% greater than that of the
surrounding vessel wall or as a focal region with IMT greater than 1.5 mm that protrudes into
the lumen. Both near and far walls can be used for assessment of the IMT. However, IMT of
the near wall is less accurate because the ultrasound beam is traveling from more to less
echogenic layers at the adventitia-media and intima-lumen interfaces of the near wall [44].
Histological data suggest an underestimation of the IMT around 20% when the near wall is
used [45]. A linear-array transducer operating at a frequency of at least 7 MHz [44]. Three
methods most frequently used to measure the IMT by using B –Mode are the following: 1.
Averaging the maximum IMT of the four far walls of the carotid bifurcations and of the distal
common carotid arteries. 2. Assessing the mean maximum thickness (M max) of up to 12
different sites (right and left, near and far walls, distal common, bifurcation, and proximal
internal carotid). 3. The maximum measured IMT of a single measurement is taken into
account. The last method provides more reproducible results when IMT measurement is
restricted to the far wall of the distal segment of the common carotid artery, providing only a
3% of relative difference between two successive measurements [46]. Analysis may be
performed by manual cursor placement or by automated computerized edge detection. As we
mentioned above, B-mode imaging is preferred over M-mode imaging. M-mode, in spite of a
superior temporal resolution, provides measurement of one single point of thickness, rather
than a segmental value as it is enabled by B-mode. However, carotid wall thickening is not
uniform and a singe point measurement may not represent accurately the arterial status and
is less reproducible for follow-up measurements. A novel noninvasive echo-tracking system
measuring the IMT and other mechanical properties of the carotid wall has been proposed [47].
This method enables an additional evaluation of the carotid plaque stability and composition.
The normal IMT values are influenced by age and sex and IMT normal values may be defined
in terms of statistical distribution within a healthy population. IMT values greater than the
75th percentile are considered high and indicate an increased cardiovascular risk. Values in
the 25th to 75th percentile are considered average and indicative of unchanged CVD risk.
Values less than or equal to 25th percentile are associated with a low CVD risk [44]. However,
available data indicate that IMT > 0.9 mm represents a risk of myocardial infarction and/or
cerebrovascular disease and in the clinical practice this cut-off value may better defined in
terms of increased risk [48]. Recent data have further strengthened the relationship of carotid
IMT and plaques with cardiovascular events. A new report from the European Lacidipine
Study on Atherosclerosis (ELSA) trial suggests that baseline carotid IMT predicts cardiovas‐
cular events independent of blood pressure and this occurs both for the IMT value at the carotid
bifurcations and for the IMT value at the level of the common carotid artery [49]. The adverse
prognostic significance of carotid plaques has also been reported in patients with high normal
blood pressure prospectively followed for about 13 years [50]. In the Risk Intervention Study
(RIS) study patients with severe essential hypertension and high cardiovascular risk had a
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significantly higher prevalence of atherosclerotic lesions compared to control subjects [51].
Assessment of IMT plays an important role in the risk stratification. Interestingly, about 30%
of hypertensive subjects classified as at low or moderate added risk without ultrasound for
carotid artery thickening or plaque were placed in the high added risk group after detecting
of vascular damages [29].
The predictive value of the carotid ultrasound and its role in risk stratification has been
demonstrated in a lot of trials as aforementioned. Whether a decrease of IMT progression is
associated with a reduction of cardiovascular events and an improvement in prognosis
remains at the time elusive. Therapeutic double blind trials have shown that antihypertensive
drugs may have a more or less marked effect on carotid IMT progression. A recent meta-
analysis of 22 randomized controlled trials has evaluated the effects of an antihypertensive
drug versus placebo or another antihypertensive agent of a different class on carotid intima-
media thickness. The results have shown that compared with no treatment, diuretics/± beta-
blockers, ACE inhibitors and calcium antagonists attenuate the rate of progression of carotid
intima-media thickening, in some trials even in the absence of any significant reduction of the
blood pressure [52]. In patients with hypertension and hypercholesterolemia the administra‐
tion of pravastatin prevents the progression of carotid intima-media thickness [53]. In the ELSA
trial the treatment-induced changes of the IMT did not predict cardiovascular events as was
the case by the baseline values. However, these results are not conclusive due to the smallness
of the IMT changes and the large individual differences in baseline IMT [49].
Beyond the identification of subclinical organ damage of the carotid arteries, ultrasound is a
useful tool for identification of carotid stenoses in progressive atherosclerosis. High blood
pressure is a major risk factor for stroke with a correlation between elevated BP and occurrence
of stroke. This correlation holds over a wide BP range, from systolic levels as low as 115 mm/
Hg and diastolic levels as low as 70 mm/Hg [54], with systolic BP having a stronger association
with higher stroke risk. Elevated BP is positively associated with both ischemic and hemor‐
rhagic stroke, with a higher association appearing in hemorrhagic stroke and secondary
prevention [56]. Large vessel disease of the extracranial arteries accounts for half of the
ischemic strokes.
Doppler sonography is the most common imaging study performed for the diagnosis of carotid
disease. It is part of the imaging tests taking place early after a transient ischemic attack (TIA)
or stroke in order to identify patients with tight symptomatic arterial stenosis who could
benefit from endarterectomy or angioplasty. Carotid Doppler-studies are fast, non-invasive
and easily applicable however provide limited information, require skilled operators and are
investigator-dependent. Doppler ultrasound has a similar specificity and sensitivity for carotid
artery stenosis with computed tomography angiography (CTA) but both are inferior to
contrast-magnetic resonance angiography (MRA) [57]. For asymptomatic patients with
hypertension, assessment for carotid artery stenosis is also useful as part of risk stratification
and is recommended for patients with two or more risk factors for atherosclerosis. Evidence
of an internal carotid artery stenosis (ICA) supports recommendation of antiplatelet therapy
and more strict control of risk factors to prevent stroke [58].
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The first step of a carotid ultrasound test is to identify plaques via B-mode as referred above.
Addition of color Doppler enables identification of origin and course of the internal carotid
artery and a differentiation between severe stenosis and occlusion. Stenotic areas are identified
in the presence of the “aliasing” phenomenon occurring due to high velocities in the center of
the stenotic lumen and post-stenotic flow disturbances. Flow velocities in the spectral analysis
are the main parameters used for evaluating the severity of carotid stenosis. Flow velocity must
be sampled through the whole area of presumed stenosis until the distal end of the plaque is
seen to ensure that the site of the highest velocity has been detected. Compared to angiographic
data, a wide range of flow velocities was recorded for any given degree of angiographic
stenosis so that the sensitivity and specificity of the method may vary [59]. A better correlation
to angiographic determined stenoses is achieved by assessing the peak systolic velocity in the
internal carotid artery and the ratio of the peak systolic velocity in the internal carotid artery
to that in the ipsilateral common carotid artery as proposed by the current guidelines [60].
Based on Doppler sonography, carotid stenoses are classified into two grades: Grade 1- with
the rate of stenosis measuring between 50% to 69% and Grade 2 measuring 70-99%, which also
represents a severe non-occlusive disease. In equivocal cases, further imaging methods may
be additionally used. In Table 1 the sonographic criteria for grading of carotid artery stenosis
are summarized.
An ultrasound examination for detection of carotid stenoses and plaques and evaluation of
the intima-media thickness should be performed in hypertensive patients with concomitant
risk factors such as smoking, dyslipidemia, diabetes, obesity and family history of cardiovas‐
cular disease. The results can be useful for re-assessing CVD risk in some asymptomatic
patients and consequently re-assessing therapeutic strategies. For accurate results, strict
attention to quality control in image acquisition, measurement and interpretation are neces‐
sary.
Grade of Stenosis Peak systolic velocity and visible criteria
no stenosis < 125 cm/s and no visible plaque or IMT
< 50% < 125cm/s with visible plaque or IMT
50-69% 125 – 230 cm/s with visible plaque
> 70% to near occlusion > 230cm/s with visible plaque and lumen narrowing
100% No detectable patent lumen and flow is seen
Table 1. Grading of internal carotid artery stenosis upon Doppler velocities and B-mode
6. Flow mediated dilation
Endothelial function is linked to cardiovascular risk factors and provides prognostic informa‐
tion for cardiovascular diseases [61]. Endothelial dysfunction is regarded as the initial step of
atherosclerosis and therefore as the earliest detectable manifestation of vascular end-organ
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damage. It can be assessed using several methods, with flow-mediated dilation (FMD) being
currently the gold-standard in non-invasive evaluation of endothelial dysfunction. In this
ultrasound-based method brachial artery diameter is measured before and after an increase
in shear stress that is induced by reactive hyperemia. When a sphygmomanometer cuff placed
on the forearm or upper-arm and is inflated at 50 mm/Hg above systolic pressure, arterial
inflow is occluded causing a local ischemia and dilation of downstream arteries. Cuff deflation
induces a high-flow state through the brachial artery (reactive hyperemia) to accommodate
the dilated resistance vessels. The increased shear stress leads to endothelium dependent
dilation of the brachial artery. FMD occurs predominantly as a result of local endothelial
release of nitric oxide. Figure 1 shows the B-mode and Doppler flow images of the brachial
artery of a patient with hypertension at baseline and after deflation of the cuff (hyperemia).
The FMD was calculated by the equation: FMD = (diameter hyperemia – diameter baseline) *
100 / diameter baseline. A value of 8.1% suggesting a near normal value (>8%) was found.
By using invasive and non-invasive methods impaired endothelial function has been found in
uncomplicated hypertensive patients [62, 63]. In one prospective trial a reduction of blood
pressure in response to antihypertensive treatment leads to improvement of the FMD sug‐
gesting a beneficial effect of antihypertensive treatment on endothelial function [64]. Several
other large trials have found relationships between endothelial dysfunction assessed by FMD
and prognostic markers of cardiovascular disease and atherosclerosis [65, 66]. Although the
FMD test has opened a new field in the clinical research of conduit artery endothelial biology,
some practical challenges of this technique have prevented its broad use in daily clinical
practice so far. The most important of these are the need for highly trained operators, the time-
consuming analysis of results and the care required to minimize environmental or physiolog‐
ical influences such as eating, caffeine ingestion and variations of temperature [67].
Figure 1. Ultrasound images during testing of the flow mediated dilation. A slightly increase of the brachial diameter
from 5.44mm at baseline to 5.88mm under hyperemia was recorded. The Doppler flow shows an increase of the
blood flow after deflation of the cuff (hyperemia).
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7. Conclusions
In summary, sonography is essential in the workup of a hypertensive patient. Abdominal
sonography should be performed in the evaluation of hypertension. The last European
guidelines have emphasized that treatment-induced changes of organ damage affect the
incidence of cardiovascular events, thereby recommending performance of organ damage
examinations including sonography during treatment. When a search for secondary hyper‐
tension is indicated, abdominal sonography and Doppler ultrasound of the renal arteries are
also recommended. Table 2 summarizes the use of ultrasound in the evaluation of hyperten‐
sion.
Ultrasound examination Use in diagnostic workup of hypertension
Abdominal ultrasound Identification of subclinical and end-organ damage (recommended)
• Aortosclerosis
• Aortic aneurysm
• Nephrosclerosis
Screening for secondary causes of hypertension
• Renal parenchymal disease
• Renal vascular disease
• Adrenal adenomas
• Phaeochromocytoma
Echocardiography Identification of subclinical and end organ damage (recommended)
• Left ventricular hypertrophy (LVH)
• Systolic and diastolic dysfunction
• Left atrium dimension and geomertry
Doppler ultrasound of the renal arteries Screening for secondary causes of hypertension
• Renovascular hypertension
Ultrasound of the carotid arteries Identification of subclinical and end-organ damage (recommended)
• Intima – media thickness (IMT)
• Carotid plaques
• Carotid artery stenosis
Assessment of flow-mediated dilation of
brachial artery
Identification of subclinical organ damage (not in clinical use)
• Endothelial dysfunction
Table 2. Ultrasound examinations in hypertension
In summary, sonography is essential in the workup of a hypertensive patient. Abdominal
sonography should be performed in every newly diagnosed case of hypertension. Performance
of further ultrasound techniques depends on age, concomitant diseases, symptoms, and
overall cardiovascular risk. Table 2 summarizes the use of ultrasound in the evaluation of
hypertension.
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